Mirae Asset Global Etfs Holdings Ltd. Trevi Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 21,151 shares of TRVI stock, worth $61,549. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,151Holding current value
$61,549% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
78Shares Held
54.3MCall Options Held
15.6KPut Options Held
0-
Nea Management Company, LLC Timonium, MD11.4MShares$33.1 Million3.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$21.5 Million1.3% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$14.6 Million0.44% of portfolio
-
Viking Global Investors LP4.4MShares$12.8 Million0.05% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$9.96 Million1.12% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $170M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...